RadioNano Therapeutics㈱
Kyoto, JP · 4 known investors
Find your way into RadioNano Therapeutics㈱
31 people in our graph share verified history with the RadioNano Therapeutics㈱ team — schools, employers, funds. One of them is your warm intro.
Fuyuki Yamaguchiunlockedknows Masatoshi Chiba · together at The University of Tokyo (overlapped)
knows the team · via Mitsubishi Tanabe Pharma Corporation
×5knows the team · via The University of Tokyo
×4knows the team · via Mitsubishi Chemical Group
knows the team · via Tokyo University of Science
RadioNano Therapeutics develops boron neutron capture therapy (BNCT), an advanced radiotherapy targeting cancer cells. The company is commercializing RN-501, a nanoparticle-enhanced therapeutic drug aimed at improving treatment safety and efficacy for cancer patients.
Founders & leadership
MC
Masatoshi ChibainCEOMasatoshi Chiba spent 36 years at Mitsubishi Chemical Group in various pharmaceutical roles including production, drug development, supply chain, research, and business development, before co-founding RadioNano Therapeutics in 2024 to commercialize a boron neutron capture therapy treatment.
HK
Hiroshi KawaiCBO/COO
Investors · 4
Frequently asked questions
- What does RadioNano Therapeutics㈱ do?
- RadioNano Therapeutics develops boron neutron capture therapy (BNCT), an advanced radiotherapy targeting cancer cells. The company is commercializing RN-501, a nanoparticle-enhanced therapeutic drug aimed at improving treatment safety and efficacy for cancer patients.
- Who are RadioNano Therapeutics㈱'s investors?
- RadioNano Therapeutics㈱'s investors include Kyoto University Innovation Capital, Japan Science and Technology Agency, Mitsubishi UFJ Capital, DBJ Capital.
- Where is RadioNano Therapeutics㈱ headquartered?
- RadioNano Therapeutics㈱ is headquartered in Kyoto, JP.